Abstract
Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Medicinal Chemistry
Title: The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers
Volume: 3 Issue: 6
Author(s): Allen B. Reitz, Suneel K. Gupta, Yifang Huang, Michael H. Parker and Richard R. Ryan
Affiliation:
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Abstract: Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Export Options
About this article
Cite this article as:
Reitz B. Allen, Gupta K. Suneel, Huang Yifang, Parker H. Michael and Ryan R. Richard, The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers, Medicinal Chemistry 2007; 3 (6) . https://dx.doi.org/10.2174/157340607782360353
DOI https://dx.doi.org/10.2174/157340607782360353 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Treatment of Retinitis Pigmentosa
Current Stem Cell Research & Therapy Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Activin-A: A New Piece in the Puzzle of Tolerance in Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Self-Assembly of DNA and Cell-Adhesive Proteins onto pH-Sensitive Inorganic Crystals for Precise and Efficient Transgene Delivery
Current Pharmaceutical Design HIV Infection Induces Morphometrical Changes on the Oral (Buccal Mucosa and Tongue) Epithelial Cells
Current HIV Research Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets The Genetics of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Identification of the Differentially Expressed Genes Involved in the Synergistic Neurotoxicity of an HIV Protease Inhibitor and Methamphetamine
Current HIV Research Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies
Mini-Reviews in Medicinal Chemistry